Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,865 across all filing types
Latest filing 2018-06-28 Regulatory Filings
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Topline results of PELICAN trial and update on triple combo development plans
Regulatory Filings Classification · 98% confidence The document is a press release dated June 28, 2018, announcing 'Topline results of PELICAN trial and update on triple combo development plans' for a clinical-stage biotechnology company (Galapagos NV). It details clinical trial results (efficacy endpoints, sweat chloride reduction, safety profile) and provides updates on ongoing and discontinued development programs. This content structure—announcing specific scientific/clinical milestones and strategic updates outside of a formal quarterly/annual filing—is characteristic of an Earnings Release (ER) or a general press release detailing operational news. Since it focuses on specific clinical trial results and strategic decisions rather than comprehensive financial statements (like 10-K or IR) or a general market announcement (RNS), the most appropriate classification is Earnings Release (ER), as these often include operational highlights alongside any financial context, or sometimes serve as the primary vehicle for such news when a formal earnings report isn't the focus. Given the focus on trial results and pipeline updates, ER is a strong fit, although it could also be considered a Regulatory Filing (RNS) if it were purely non-financial news. However, clinical trial updates are frequently bundled with ERs. Since it is not a short announcement pointing to a separate report (RPA), and it contains substantial operational detail, ER is selected.
2018-06-28 English
Resultaten van PELICAN trial en update over plannen voor drievoudige combinatietherapie in CF
Earnings Release Classification · 95% confidence The document is a press release dated June 28, 2018, announcing clinical trial results (PELICAN trial) for a drug candidate (GLPG2737) and providing an update on development plans for triple combination therapy in Cystic Fibrosis (CF). It details scientific findings (sweat chloride reduction, ppFEV1 trend) and strategic decisions (AbbVie partnership update). This format—a formal announcement of scientific/operational progress, often including financial/strategic context but not being a full annual or quarterly financial report—is characteristic of an Earnings Release (ER) or a general announcement. Since it focuses heavily on clinical trial results and strategic pipeline updates rather than just summarizing period financial performance (which would be ER), and it is not a full regulatory report (like 10-K or IR), it fits best as an Earnings Release (ER) if the context implies it accompanies quarterly results, or potentially an Investor Presentation (IP) if it were structured as slides. Given the structure as a formal press release detailing key results and strategic moves, ER is the most appropriate fit among the options for a significant operational update, although it lacks explicit quarterly financial tables. However, since it is a formal announcement of results and strategic updates, and not a short notice about a report being available (RPA/RNS), ER is the strongest classification for this type of corporate communication detailing operational milestones. Q2 2018
2018-06-28 Dutch
Servier and Galapagos announce start of global ROCCELLA Phase 2 clinical trial with S201086/GLPG1972 in osteoarthritis patients
Regulatory Filings Classification · 93% confidence The document is a joint press release from Servier and Galapagos announcing the start of a global Phase 2 clinical trial (ROCCELLA) for a drug candidate (S201086/GLPG1972) in osteoarthritis patients. It details the trial design, objectives, mechanism of action, and financial milestones related to the collaboration. This type of announcement, detailing clinical trial progress and partnership updates, is characteristic of communications aimed at investors and the public regarding ongoing drug development. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). Since it is a specific announcement about a clinical development milestone and partnership activity, it fits best under the general category of Investor/Corporate information, but none of the specific codes (like LTR for legal or CAP for financing) perfectly capture a clinical trial initiation announcement. However, given the context of drug development updates, it is most closely related to general corporate/investor news. Since it is a detailed announcement about a specific corporate/development event, and not a short notice about a report being published (RPA/RNS), it should be classified based on its content. In the absence of a specific 'Clinical Trial Update' code, this type of detailed corporate development news often falls under general Regulatory Filings (RNS) if it's a required disclosure, or sometimes Investor Presentation (IP) if it were a slide deck, but here it is a press release. Given the options, and recognizing this is a significant corporate development announcement, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for a press release detailing clinical trial initiation, as it is a material event disclosure.
2018-06-27 English
Servier and Galapagos announce start of global ROCCELLA Phase 2 clinical trial with S201086/GLPG1972 in osteoarthritis patients
Regulatory Filings Classification · 95% confidence The document is a press release dated June 26, 2018, announcing the start of a global Phase 2 clinical trial (ROCCELLA) for a drug candidate (S201086/GLPG1972) for osteoarthritis, involving Galapagos and Servier. It details the study design, objectives, mechanism of action, and quotes management. This type of announcement, detailing clinical trial initiation and partnership updates, is characteristic of an announcement related to drug development and corporate activity, but it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). Since it announces a significant corporate/development event and is structured as a press release, it most closely aligns with a general regulatory announcement or a specific announcement related to financing/capital structure if it involved a major payment, but given the context of clinical trial initiation and partnership milestones, it fits best under the general 'Regulatory Filings' (RNS) category as a significant, non-standard announcement, or potentially 'Capital/Financing Update' (CAP) due to the €9 million milestone payment mentioned. However, the primary focus is the clinical trial start. Given the options, and that it is a press release announcing a major operational/development milestone rather than a specific financial report, RNS (Regulatory Filings - general announcement) is the most appropriate fallback, although it is a very specific type of announcement. If a 'Clinical Trial Announcement' category existed, it would fit there. Comparing it to the definitions, it is not an ER, IR, 10-K, or AR. It is an announcement, not a report itself. Therefore, RNS is the best fit among the provided codes for a general corporate/clinical development press release.
2018-06-27 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV, for June 2018. It references a press release dated June 26, 2018, attached as Exhibit 99.1. The document is short (2771 characters) and primarily serves to submit the press release and incorporate it by reference into registration statements. There is no substantive financial data or detailed report content here, only an announcement of a press release filing. According to the rules, such a document is a Regulatory Filing (RNS) as it does not contain the report itself but rather a filing of a press release or other document under Form 6-K.
2018-06-27 English
Galapagos increases share capital through warrant exercises
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces a capital increase ('kapitaalverhoging') resulting from the exercise of warrants ('uitoefening van warrants'). It details the number of new shares issued, the total capital raised, and updates the total number of voting rights and shares outstanding, referencing Belgian transparency legislation regarding significant shareholdings. This content directly relates to changes in the company's capital structure and financing activities. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), as it concerns a specific capital event.
2018-06-21 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.